Last updated:  November 16, 2023 
 Sponsor:  Sofwave Medical LTD 
 Overall Status: Completed
Phase
 N/A 
Condition
Skin Aging
Treatment
Sofwave
Clinical Study ID
 NCT04969380 
 UCI IRB HS# 2019-5520 
 Ages 35-80 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Healthy female and male subjects between the ages 35-80.
 - Non-Smoker.
 - Fitzpatrick skin type I-VI.
 - Desire to lift lax skin in the neck and submental and/or to lift the brows.
 - Able and willing to comply with all visit, treatment and evaluation schedules andrequirements.
 - Able to understand and provide written Informed Consent
 - Women of child-bearing age are required to be using a reliable method of birth controlat least 3 months prior to study enrollment.
 
Exclusion
Exclusion Criteria:
- Pregnant or planning to become pregnant, having given birth less than 3 months ago,and/or breast feeding.
 - Presence of any active systemic or local infections.
 - Presence of active local skin disease that may alter wound healing.
 - Severe solar elastosis.
 - History of smoking in past 10 years.
 - History of chronic drug or alcohol abuse.
 - Excessive subcutaneous fat on the cheeks.
 - Significant scarring in the area to be treated.
 - Severe or cystic facial acne, acutance uses during past 6 months.
 - Presence of a metal stent or implant in the facial area (dental implants and/or bracesare not excluded).
 - Inability to understand the protocol or to give informed consent.
 - History of cosmetic treatments in the facial area to be treated, including facialskin-tightening procedure within the 6 months ; injectable (Botox or fillers) of anytype within the 6 months; ablative or non-ablative resurfacing/rejuvenation lasertreatment or light treatment within the past 6 months, dermabrasion or deep facialpeels within the past 12 months; facelift, blepharoplasty, or brow lift (includingcontour threads) within the past 12 months.
 - Taking Isotretinoin or other oral retinoid within the past 6 months; takinganti-platelet or anti-coagulant within the past 2 weeks.
 - As per the investigator's discretion, any physical or mental condition which mightmake it unsafe for the subject to participate in this study.
 
Study Design
Total Participants: 20
Treatment Group(s): 1
Primary Treatment:  Sofwave
Phase:  
Study Start date:
February 27, 2020
Estimated Completion Date:
February 27, 2023
Study Description
Connect with a study center
University of California
Irvine, California 92697
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.